Cervical cancer technology company, TruScreen Limited (NZAX:TRU), announces that it has now commenced the large scale Chinese evaluation (previously advised) with The Women’s and Children’s Division of the Centre for Disease Control (CDC).
The aim of the evaluation is multifold: To have TruScreen included in the CDC’s screening guidelines for the 3000 hospitals run by its Women’s and Children’s Health Division; to have the CDC recommend TruScreen for inclusion in the Central Government’s Ministry of Health screening guidelines for all 12,000 government hospitals in China; and, as part of the evaluation, TruScreen will also be assessed for use as a first choice screening technology in rural areas in China.
The evaluation will involve a minimum of 12,000 women across eight provinces and 16 hospitals in China is expected to generate $162,000 revenue for TruScreen during the next three months.
Chairman of TruScreen, Robert Hunter, said: “we are extremely confident of TruScreen’s Clinical capabilities and this pilot program is an essential component to gaining acceptance by the Chinese national healthcare administrators and for inclusion in the National Cervical Screening guidelines. When complete, this endorsement will be the key to TruScreen gaining access to over 3,000 hospitals and a share of the 10 million Central Government funded screening tests conducted in these hospitals each year.”
The CDC is responsible for conducting Central Government sponsored screening programs in China, for cervical cancers, through its hospitals and the Central Government Ministry of Health directly funds these 10 million cervical cancer screening tests per year through CDC hospitals, which is a market valued in excess of $75 million per annum.
With 400 million women of screening age, China remains our primary market opportunity and we have experienced significant increase in sales since CFDA approval was received at the end of 2017.